HBX 41108

HBX 41108 is an inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 of 424 nM. HBX 41108 inhibits USP7-mediated p53 deubiquitination to stabilize p53 and inhibits cancer cell growth. BX 41108 can be used in cancer and diabetes research[1][2][3][4].

Product Specifications

CAS Number

[924296-39-9]

UNSPSC

12352005

Hazard Statement

H317-H319

Target

Apoptosis; Deubiquitinase; MDM-2/p53

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/hbx-41108.html

Purity

98.91

Solubility

DMSO : 250 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

N#CC1=C(C#N)N=C2C(C(C3=C2C=CC(Cl)=C3)=O)=N1

Molecular Formula

C13H3ClN4O

Molecular Weight

266.64

Precautions

P261-P264-P272-P280-P302+P352-P305+P351+P338-P362+P364-P501

References & Citations

[1]Colland F, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8 (8) :2286-95. |[2]Colombo M, et al. Synthesis and biological evaluation of 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarbonitrile analogues as potential inhibitors of deubiquitinating enzymes. ChemMedChem. 2010 Apr 6;5 (4) :552-8. |[3]Li X, Wang T, et al. Inhibition of USP7 suppresses advanced glycation end-induced cell cycle arrest and senescence of human umbilical vein endothelial cells through ubiquitination of p53. Acta Biochim Biophys Sin (Shanghai) . 2022 Mar 25;54 (3) :311-320. |[4]Li X, Wang T, et al. Inhibition of USP7 suppresses advanced glycation end-induced cell cycle arrest and senescence of human umbilical vein endothelial cells through ubiquitination of p53. Acta Biochim Biophys Sin (Shanghai) . 2022 Mar 25;54 (3) :311-320. |[5]Nawa Y, et al. Functional characterization of the neuron-restrictive silencer element in the human tryptophan hydroxylase 2 gene expression. J Neurochem. 2017 Sep;142 (6) :827-840.